Australia markets closed

PharmAust Limited (PAA.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1050+0.0050 (+5.00%)
At close: 04:10PM AEDT

PharmAust Limited

5/3 Brodie Hall Drive
Bentley, WA 6102
61 8 9202 6814

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICDFinance Director, Company Secretary & Non-Executive Director138kN/A1978
Mr. Robert Charles Bishop LLB (Hons)Executive Director141.44kN/AN/A
Ms. Fiona MilnerGeneral Manager of Epichem Pty Ltd212.1kN/AN/A
Dr. Michael Thurn Ph.D.CEO & DirectorN/AN/AN/A
Dr. Gary PittHead of ChemistryN/AN/AN/A
Dr. James RixsonHead of ProductionN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Corporate governance

PharmAust Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.